Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.53 |
| ▸ | CCR1 | P32246 | 3/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29875592 | 1.00 | ELANE (0.53) | ELANECCR1RORCKDM4ERECQL | |
| SCHEMBL4021451 | 0.89 | ELANE (0.56) | ELANECCR1NOTUMALDH1A1 | |
| SCHEMBL11895082 | 0.87 | ELANE (0.53) | ELANECCR1RECQLNOTUMPPARG | |
| SCHEMBL11894815 | 0.87 | ELANE (0.54) | ELANECCR1RORCNOTUMALDH1A1 | |
| SCHEMBL4022960 | 0.86 | ELANE (0.55) | ELANECCR1 | |
| SCHEMBL4021150 | 0.86 | ELANE (0.53) | ELANECCR1NOTUMALDH1A1 | |
| SCHEMBL4024041 | 0.85 | CCR1 (0.54) | ELANECCR1NOTUMALDH1A1 | |
| SCHEMBL5759847 | 0.84 | ELANE (0.74) | ELANECCR1RORCKDM4ERECQL | |
| SCHEMBL11895339 | 0.84 | ELANE (0.50) | ELANECCR1KDM4ENOTUMALDH1A1 | |
| SCHEMBL11895008 | 0.84 | ELANE (0.51) | ELANECCR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367178-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12226407-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4491180-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Avalyn Pharma Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3091976-B1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2023-05-18 | — | — | US | disclosed |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11452718-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2022-07-14 | — | — | US | disclosed |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | AVALYN PHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | AVALYN PHARMA INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20150196543-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2015-07-16 | — | — | US | disclosed |
| WO-2015106150-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| EP-2877164-A2 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS | Genoa Pharmaceuticals, Inc. (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014018668-A2 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | WO | disclosed |
| EP-2670242-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | Genoa Pharmaceuticals, Inc. (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130310424-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | AVALYN PHARMA INC. | 2013-11-21 | — | — | US | disclosed |
| WO-2012106382-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | GENOA PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-1663974-B1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149375-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-11224592-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-20150196543-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-20220218683-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-20070043036-A1 | 2-Pyridone derivatives as neutrophil elastase inhibitors and their use | SERPINB1, ELANE, SERPINE1 | ELANE 2/4885CCR1 211/4885RORC 2765/4885 |
| US-11559520-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-20250367178-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-20120192861-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-11452718-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-12226407-B2 | Aerosol pirfenidone and pyridone analog compounds and uses thereof | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-20130310424-A1 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF | PLPBP, PIR, PDXK | ELANE 1574/4885CCR1 1988/4885RORC 1496/4885 |
| US-11071741-B2 | Aerosol pirfenidone and pyridone analog compound and uses thereof | PLPBP, PIR, PDXK | ELANE 1543/4885CCR1 2045/4885RORC 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.